Deal News

  • 20 May 2019

    Parvus and Genentech to develop treatment options in gastroenterology

    Biopharmaceutical firm Parvus Therapeutics has signed a worldwide collaboration and licence agreement with Genentech to develop, manufacture and commercialise therapeutics for inflammatory bowel disease (IBD), autoimmune liver diseases (ALD) and coeliac disease...

  • 16 May 2019

    Biogen’s SMA drug Spinraza to be available on NHS

    The UK's National Health Service (NHS) has signed a managed access agreement to fund Biogen’s antisense oligonucleotide (ASO) Spinraza (nusinersen) for a limited time to ascertain its effectiveness as a...

  • 10 May 2019

    Gilead and Goldfinch Bio enter drug development deal

    Gilead Sciences has partnered with biotechnology firm Goldfinch Bio for the discovery, development and commercialisation of new drug candidates to potentially treat diabetic kidney disease (DKD) and selected orphan kidney...

Go Top